Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment.
about
Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switchChanges in matrix metalloproteinase-9 levels during progression of atrial fibrillationRedox signaling, vascular function, and hypertension.Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases.Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension.Angiotensin-II induced hypertension and renovascular remodelling in tissue inhibitor of metalloproteinase 2 knockout mice.Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.Reduced NO signaling during pregnancy attenuates outward uterine artery remodeling by altering MMP expression and collagen and elastin depositionGene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: from the Dallas Heart Study.Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular diseaseProtein Kinase C Inhibitors as Modulators of Vascular Function and their Application in Vascular DiseaseMatrix metalloproteinases as drug targets in preeclampsiaSerum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 DiabetesRelations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community.Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications.Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease.Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease.Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives.Cerebrovascular gene expression in spontaneously hypertensive rats.Gene expression profiling of aging in multiple mouse strains: identification of aging biomarkers and impact of dietary antioxidants.Metalloproteinase-3 genotype as a predictor of cardiovascular risk in hypertensive adolescents.Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension.Family history of hypertension, anthropometric parameters and markers of early atherosclerosis in young healthy individuals.Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats.Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.Role of MMP-2 (-1306 C/T) Polymorphism in Age-Related Macular Degeneration.Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naïve patients with hypertension with atherosclerosis.Resistance training and caloric restriction prevent systolic blood pressure rise by improving the nitric oxide effect on smooth muscle and morphological changes in the aorta of ovariectomized rats
P2860
Q26849388-7F01AF3A-A332-4CBB-99F1-C295194BB08AQ28304239-D7F26362-D12D-403E-8561-C0E1B99D01A7Q33689229-AD394F07-A664-4B7C-B28B-6449C59040F6Q33872836-8C62424A-A212-41A6-BB5D-9D6B92AEF804Q33904413-3B957359-B432-44BB-9160-BE5AFE72B1BCQ34009450-C3628F3A-E451-456A-843E-B413AD6DFB63Q35001863-CF9CAAE7-C1B9-4D4C-9659-4C5C3B1F28C9Q35176333-73298E97-658A-4B25-AEE7-2BC2EC1D7932Q35395483-1CF2AF2D-A387-488E-9EAF-A6DDE14A068FQ35886165-E386E0E8-CBDC-4F14-8CC7-9A8017432405Q36009930-3AFFB982-24F9-4AFA-AD94-A5D3A82986ABQ36469686-DEA89CB0-FCBD-4164-8A70-9C225985B64DQ36477722-12ED7C77-1469-49B4-BA15-E53F4A1D2CCAQ36748065-15BF1E98-6BC1-44FC-A877-B19EDF390CE1Q36910638-BECD1D90-937D-457B-8A29-2D996FB3C762Q37209809-2E33CCC4-D485-40FC-BD57-34CC2B5A4B3DQ37312630-1D58EF28-1446-4545-A1C8-FAA993B8F7BEQ37993746-3C184926-B02A-43BC-8819-984F0F93F50AQ38040163-DC0B50CF-256B-477E-A4EF-0D3D5BD69CEEQ38061567-D1858F08-DB18-4F9D-998F-5F51248FC537Q39208841-58CFA8F8-B875-4B9A-BC1E-FDCE7B273EFCQ41571459-84829E2F-691E-496A-A1A4-02448C4E2947Q41866466-5F9CF34F-DD15-4FBC-9C34-7B8C7020915FQ42130552-58C3BA52-83C0-4A18-9CEB-B24AE7608A6BQ43230192-EC7A7A8B-F29E-44AF-AC44-7919404F467AQ46064721-27233ADE-9DBC-4837-B730-7332E759CD7EQ46307244-CB723890-1213-4CF1-A50D-8473280D1D8AQ48161084-6510480E-4A7C-45E3-88A3-3C3F03D39B0CQ50916304-EA254281-A61B-4738-80B2-DA0EFF3A309CQ50989102-FBEBD575-FBAA-4C3B-AAA7-A6CD59C3D3E6Q54373020-2AE04149-B4CF-4563-B7FE-1CE40BE41E13Q58723260-03EA0AAF-EF02-4241-9D94-973E925941FC
P2860
Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Plasma levels of active extrac ...... er antihypertensive treatment.
@en
Plasma levels of active extrac ...... er antihypertensive treatment.
@nl
type
label
Plasma levels of active extrac ...... er antihypertensive treatment.
@en
Plasma levels of active extrac ...... er antihypertensive treatment.
@nl
prefLabel
Plasma levels of active extrac ...... er antihypertensive treatment.
@en
Plasma levels of active extrac ...... er antihypertensive treatment.
@nl
P2093
P2860
P356
P1476
Plasma levels of active extrac ...... er antihypertensive treatment.
@en
P2093
Economou E
Pitsavos C
Stefanadis C
Toutouza M
Toutouzas P
Tsioufis K
Vasiliadou K
Zervoudaki A
P2860
P2888
P304
P356
10.1038/SJ.JHH.1001518
P577
2003-02-01T00:00:00Z